A Phase 3 registration study of Sotigalimab in combination with doxorubicin as a treatment of patients with anthracycline-naive, advanced LPS.
Latest Information Update: 04 Sep 2023
At a glance
- Drugs Doxorubicin (Primary) ; Sotigalimab (Primary)
- Indications Liposarcoma
- Focus Registrational; Therapeutic Use
- Sponsors Apexigen; Pyxis Oncology
Most Recent Events
- 23 Aug 2023 According to Pyxis Oncology, Inc media release, Apexigen has been acquired by Pyxis Oncology.
- 25 Nov 2022 New trial record